PMID: 16506528Mar 2, 2006Paper

rAAt (dermatological) Arriva/ProMetic

Current Opinion in Molecular Therapeutics
William M Brown

Abstract

Arriva Pharmaceuticals Inc and ProMetic Life Sciences Inc are developing a gel formulation of recombinant alpha1-antitrypsin (rAAT). The therapy, as a topical formulation, is in phase II clinical trials for the potential treatment of atopic dermatitis and severe dermatological disorders. rAAT is also under preclinical investigation for the potential treatment of other inflammatory skin conditions, including psoriasis, as well as for otitis media.

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Related Papers

Current Opinion in Molecular Therapeutics
William M Brown
The Laryngoscope
Patrick J AntonelliPhilip J Barr
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
Patrick J AntonelliPhilip J Barr
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
© 2021 Meta ULC. All rights reserved